Author details

Full Name

Zhenlin Ju

Affiliation

ORCID

Career Start Year

2000

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36658425	Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.	Nat Med	2023
36930815	Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.	Cancer	2023
35296281	Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer.	BMC Cancer	2022
35682810	Adaptation and Changes in Actin Dynamics and Cell Motility as Early Responses of Cultured Mammalian Cells to Altered Gravitational Vector.	International Journal of Molecular Sciences	2022
35869155	The molecular heterogeneity of the precancerous breast affects drug efficacy.	Scientific Reports	2022
36205581	RPPA SPACE: an R package for normalization and quantitation of Reverse-Phase Protein Array data.	Bioinformatics	2022
33658639	Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling.	Br J Cancer	2021
33546743	Transcriptomic and metabolomic profiling reveal the p53-dependent benzeneacetic acid attenuation of silica-induced epithelial-mesenchymal transition in human bronchial epithelial cells.	Cell and Bioscience	2021
33157050	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.	Cancer Cell	2020
32081846	Immuno-genomic landscape of osteosarcoma.	Nat Commun	2020
31780779	Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.	Br J Cancer	2020
32037399	Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.	Br J Cancer	2020
32204397	Integrative Analyses of Multilevel Omics Reveal Preneoplastic Breast to Possess a Molecular Landscape That is Globally Shared with Invasive Basal-Like Breast Cancer (Running Title: Molecular Landscape of Basal-Like Breast Cancer Progression).	Cancers	2020
33092312	Erratum: Ju, Z., et al. Integrative Analyses of Multilevel Omics Reveal Preneoplastic Breast to Possess a Molecular Landscape That Is Globally Shared with Invasive Basal-Like Breast Cancer (Running Title: Molecular Landscape of Basal-Like Breast Cancer Pr	Cancers	2020
32917656	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.	Cancer Immunol Res	2020
33027286	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA.	PLoS One	2020
33016929	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors.	J Clin Invest	2020
32726703	A gut dysbiotic microbiota-based hypothesis of human-to-human transmission of non-communicable diseases.	Science of the Total Environment	2020
31191824	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.	Oncotarget	2019
31623857	Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.	Gynecol Oncol	2019
30482774	PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.	Cancer Res	2019
31185210	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.	Cancer Cell	2019
29736026	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.	Nat Med	2018
30268436	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î² Superfamily.	Cell Syst	2018
30389923	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.	Nat Commun	2018
30333037	Essential roles of mitochondrial biogenesis regulator Nrf1 in retinal development and homeostasis.	Mol Neurodegener	2018
29533785	Systematic Functional Annotation of Somatic Mutations in Cancer.	Cancer Cell	2018
29533782	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.	Cancer Cell	2018
29531020	Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies.	Mol Cell Proteomics	2018
28196595	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.	Cancer Cell	2017
28659310	DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of KrÃ¼ppel-Like Factor 4 Expression.	Clin Cancer Res	2017
28566428	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers.	Sci Transl Med	2017
28439535	A murine preclinical syngeneic transplantation model for breast cancer precision medicine.	Sci Adv	2017
28649435	Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm.	NPJ Syst Biol Appl	2017
29291005	Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients.	Oncotarget	2017
28202507	YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.	Cancer Res	2017
26685214	Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts.	Mol Cancer Res	2016
27172895	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype.	Clin Cancer Res	2016
26061751	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.	N Engl J Med	2015
25629879	Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas.	Nat Commun	2015
25644622	Prognostic relevance of acquired uniparental disomy in serous ovarian cancer.	Mol Cancer	2015
25380958	Development of a robust classifier for quality control of reverse-phase protein arrays.	Bioinformatics	2015
26439496	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.	Cancer Cell	2015
26045339	PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.	Mol Oncol	2015
26069190	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.	Cancer Discov	2015
24871328	A pan-cancer proteomic perspective on The Cancer Genome Atlas.	Nat Commun	2014
25284480	Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.	Cancer Cell	2014
25501559	Spatial normalization of reverse phase protein array data.	PLoS One	2014
25374453	A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data.	Cancer Inform	2014
24395800	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.	Proc Natl Acad Sci U S A	2014